You are here:
LinkedIn-button

News

Check here for our latest news

Intravacc launches hybrid business model to drive innovation and growth

Intravacc launches hybrid business model to drive innovation and growth Bilthoven, the Netherlands, 16 September 2021 – Intravacc, a global leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, today launches its new hybrid…

  • Hybrid model: CDMO services and development of a proprietary vaccine pipeline
  • Intravacc will also put emphasis on the therapeutic vaccine market
  • Intravacc’s proprietary vaccine portfolio will mainly focus on intranasal administration
  • Intravacc launches promotional campaign, supporting the funding of a phase I clinical trial with the Avacc 10 nasal spray vaccine
Read more

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the…

  • Sabin-IPV polio vaccine developed by Intravacc contributes to the eradication of polio
  • Sinovac’s polio vaccine (sIPV) receives market authorization from the NMPA in China
  • Intravacc’s cell technology also used for the development of Sinovac’s Covid-19 vaccine that was introduced on the market recently and is currently under rolling review by EMA
Read more

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme…

  • Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
  • Two conventional vaccines based on Intravacc's OMV platform and VEO cell platform
Read more

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results…

  • Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
  • Intranasal vaccine administration has significant advantages over injectables
  • OMV technology is a powerful vaccine platform for future pandemics
Read more

Intravacc announces formation of Scientific Advisory Board

Intravacc announces formation of Scientific Advisory Board Bilthoven, the Netherlands, 23 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board (“SAB”), chaired by Intravacc’s Chief Scientific…

Read more
LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.